Related Experiment Video
Updated: Nov 24, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Research Progress of Targeted Therapy for HER2 Gene in Advanced Non-small Cell Lung Cancer]
Lingping Kong1, Diansheng Zhong1
1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Abstract:
Lung cancer is the most common malignancy tumor. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer. Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor in ERBB/HER family, which activates downstream signal transduction with other family members such as epidermal growth factor receptor (EGFR). HER2 gene mutation is closely related to the progression of many epithelial cell cancers. Tumors with high expression of HER2 show strong metastasis and invasion ability, poor sensitivity to chemotherapy, and are prone to relapse. At present, lung cancer driven gene targeted therapy has made rapid progress. Although the frequency of HER2 gene mutation in NSCLC is lower than that of EGFR, its driving mechanism in lung cancer is clear and partial targeted therapy is effective, which may become a new standard treatment in the future. This review focuses on the research progress of HER2 gene mutation in the treatment of NSCLC. .
Insights
Human epidermal growth factor receptor-2 (HER2) mutations are key drivers in non-small cell lung cancer (NSCLC) progression. Targeted therapies show promise for treating NSCLC, potentially establishing a new standard of care.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is the most prevalent malignancy, with Human Epidermal Growth Factor Receptor-2 (HER2) mutations implicated in its progression.
- HER2, a tyrosine kinase receptor, plays a role in cell signaling and is linked to aggressive cancer phenotypes, including metastasis and chemoresistance.
Purpose of the Study:
- To review the research progress on HER2 gene mutations in the context of non-small cell lung cancer (NSCLC) treatment.
- To highlight the potential of targeted therapies for HER2-mutated NSCLC.
Main Methods:
- Literature review of studies investigating HER2 gene mutations in NSCLC.
- Analysis of current targeted therapy approaches and their efficacy.
Main Results:
- HER2 gene mutations, while less frequent than EGFR mutations in NSCLC, have a clear driving mechanism.
- Emerging targeted therapies demonstrate effectiveness against HER2-driven NSCLC, suggesting therapeutic potential.
Conclusions:
- HER2 mutations represent a significant area of research in NSCLC treatment.
- Targeted therapies for HER2-mutated NSCLC are advancing and may offer a new standard of care.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
